Merck & Company (MRK) Receives Price Target

Merck & Company (MRK) : Currently there are 12 street experts covering Merck & Company (MRK) stock. The most bullish and bearish price target for the stock is $80 and $57 respectively for the short term. The average price target of all the analysts comes to $65.67. The estimated standard deviation from the target is $7.3.

Merck & Company (MRK) : 13 analysts are covering Merck & Company (MRK) and their average rating on the stock is 2.08, which is read as a Buy. 6 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. A total of 7 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.


Also, Equity analysts at the Brokerage firm UBS maintains its rating on Merck & Company (NYSE:MRK). The rating major has initiated the coverage with buy rating on the shares. The Analysts at UBS raises the price target from $62 per share to $70 per share. The rating by the firm was issued on August 19, 2016.

Merck & Company (NYSE:MRK): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $62.70 and $62.39 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $62.98. The buying momentum continued till the end and the stock did not give up its gains. It closed at $62.90, notching a gain of 0.18% for the day. The total traded volume was 6,544,694 . The stock had closed at $62.79 on the previous day.

Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. The Companys Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. The Animal Health segment discovers, develops, manufactures and markets animal health products, including vaccines. The Companys animal health products are sold to veterinarians, distributors and animal producers.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.